KIMS QIP: ₹1,500 crore issue, pricing due June 2026

KIMS launches QIP to raise up to ₹1,500 crore

Krishna Institute of Medical Sciences Ltd (KIMS) has launched a qualified institutional placement (QIP) to raise up to ₹1,500 crore through a primary issuance of shares, according to a term sheet and placement document reviewed by Mint. The transaction adds to a series of disclosures the company made earlier in 2026 about exploring fundraising options, including a QIP and other instruments. The current structure points to a predominantly balance sheet-focused use of funds, with most proceeds earmarked for debt repayment. For investors, the key near-term data points are the indicative pricing, expected deal timeline, and the allocation of proceeds across the listed entity and subsidiaries.

Issue size, share count, and dilution

KIMS is offering up to 19.86 million new shares in the QIP. This represents 4.73% of the company’s pre-issue outstanding capital, as stated in the placement documents. Because the issuance is primary, it results in equity dilution for existing shareholders, with fresh shares being created and issued to institutional buyers.

Indicative pricing and discounts to market levels

The indicative placement price is set at ₹755 per share. This is described as a 3.04% discount to the day’s closing price of ₹778.65 on the National Stock Exchange. The same indicative price is also a 2.17% discount to the floor price of ₹771.73 per share.

Pricing is expected on or around Friday, as per the deal documents. The final issue price is typically determined after book-building, subject to regulatory requirements and demand from qualified institutional buyers.

Where the money will be used: debt repayment is the priority

KIMS has disclosed that the proceeds will be used for repayment or prepayment of outstanding borrowings availed by the parent entity and its subsidiaries. Within the total ₹1,500 crore raise:

• ₹910 crore is intended for clearing debt at the listed entity level.
• ₹215 crore is earmarked for debt clearance in subsidiaries, specifically Chalasani Hospitals Pvt., KIMS Hospitals Pvt., and KIMS Hospital Bengaluru Pvt.
• The remaining amount is planned for general corporate purposes.

This allocation highlights that the QIP is being positioned largely as a deleveraging exercise, with a smaller portion left flexible for broader corporate needs.

Lock-up terms for the company and promoters

The placement includes a 60-day lock-up agreement applicable to both the company and its promoting shareholders. Lock-up clauses are commonly used in such transactions to provide investors comfort that there will not be immediate additional equity supply from the issuer or key shareholders during a short period after the QIP.

Deal managers and execution structure

IIFL Capital and Jefferies India Pvt. Ltd are acting as the book-running lead managers for the QIP, as stated in the placement materials. Book-running lead managers typically oversee investor marketing, order collection, book-building, and coordination of regulatory and exchange-related processes.

Key dates investors are tracking

The QIP documentation points to a tight execution window once the offer is launched.

• Pricing for the deal is expected on or around Friday.
• Listing of the primary shares is likely to happen on or around 25 June.

These timelines matter for near-term trading dynamics, since QIP pricing and subsequent listing can influence stock supply, institutional ownership, and market expectations around fund deployment.

How this QIP fits into KIMS’ 2026 fundraising trail

Earlier in 2026, KIMS disclosed multiple steps toward a fundraising plan of up to ₹1,500 crore. The company had informed exchanges that its Board of Directors would meet on June 13, 2026, to consider and evaluate a proposal to raise funds. It also stated it was exploring multiple instruments including equity shares, fully convertible warrants, and other eligible securities, including convertible or non-convertible instruments, potentially in one or more tranches.

Separately, KIMS had disclosed that its Board approved a proposal on March 11, 2026, to raise funds up to ₹1,500 crore, described as being primarily through issuance of equity shares via a QIP or other permissible routes. The company also referenced shareholder and regulatory approvals as conditions for executing the fundraise, and indicated that the issue price would be announced later.

In another disclosure, KIMS said the transaction would be subject to shareholder approval at an extra-ordinary general meeting scheduled for June 13, 2026. KIMS also reported completing dispatch of postal ballot notices for the ₹1,500 crore QIP and publishing regulatory advertisements in leading newspapers, with e-voting running from March 17 to April 15, 2026.

Market impact: what the deal structure signals

A QIP that is explicitly directed toward repayment or prepayment of borrowings generally signals a focus on reducing leverage. In this case, KIMS has split the debt-clearing allocation between the listed entity and named subsidiaries, making the intended use more specific than a generic “corporate purposes” raise.

The indicative price at ₹755, positioned at a discount to both the day’s close and the floor price stated in the documents, provides an initial benchmark for investors to assess the likely pricing zone. The announced 60-day lock-up for the company and promoters can also be relevant for near-term supply expectations post-issue.

Key deal terms at a glance

What to watch next

The immediate next milestone is the final pricing of the QIP, expected on or around Friday, followed by listing of the new shares around 25 June. Investors will also track subsequent disclosures on the final issue price, final share count allotted within the up to 19.86 million cap, and confirmation of proceeds deployment in line with the stated debt repayment and corporate purposes buckets.